Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
To assess the safety and effectiveness of Somatuline® Depot (lanreotide) Injection when
 administered by a health care professional (HCP), the patient, the patient's partner or
 parent/guardian as part of their routine acromegaly care.
The objectives of this post-marketing observational study are to assess the safety and
 effectiveness, as measured by insulin-like growth factor-1 (IGF-1) and growth hormone (GH)
 levels, of Somatuline® Depot (lanreotide) Injection when administered by a health care
 professional (HCP), the patient, the patient's partner or parent/guardian as part of their
 routine acromegaly care. Treatment convenience and acromegaly symptom relief will also be
 assessed through questionnaires, and demographic and medical history information will be
 collected.
Inclusion Criteria:

 -  The patient must have a clinical diagnosis of acromegaly

 -  The patient must be treated with Somatuline® Depot (including patients newly
 prescribed Somatuline® Depot)

 -  The patient or legally authorized representative must be able to understand the
 protocol and give signed informed consent. Assent from the patient should also be
 obtained, where appropriate. Signed informed consent and assent must be obtained
 before any study-related activities are conducted.

 Exclusion Criteria:

 -  Symptomatic, untreated biliary lithiasis

 -  Known hypersensitivity to somatostatin analogs or related compounds (e.g., octreotide)